Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
Search for other papers by Kenneth Ka Hei Lai in
Google Scholar
PubMed
Department of Ophthalmology, Salmaniya Medical Complex, Government Hospitals, Bahrain
Search for other papers by Fatema Mohamed Ali Abdulla Aljufairi in
Google Scholar
PubMed
Department of Ophthalmology, Vicente Sotto Memorial Medical Center, Cebu City, Philippines
Search for other papers by Jake Uy Sebastian in
Google Scholar
PubMed
Search for other papers by Yingying Wei in
Google Scholar
PubMed
Search for other papers by Ruofan Jia in
Google Scholar
PubMed
Search for other papers by Karen Kar Wun Chan in
Google Scholar
PubMed
Search for other papers by Elaine Yuen Ling Au in
Google Scholar
PubMed
Search for other papers by Alan Chun Hong Lee in
Google Scholar
PubMed
Search for other papers by Chiu Ming Ng in
Google Scholar
PubMed
Hong Kong Eye Hospital, Hong Kong Special Administrative Region, China
Search for other papers by Hunter Kwok Lai Yuen in
Google Scholar
PubMed
Search for other papers by Wilson Wai Kuen Yip in
Google Scholar
PubMed
Search for other papers by Alvin Lerrmann Young in
Google Scholar
PubMed
Search for other papers by George Pak Man Cheng in
Google Scholar
PubMed
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
Hong Kong Eye Hospital, Hong Kong Special Administrative Region, China
Search for other papers by Clement Chee Yung Tham in
Google Scholar
PubMed
Search for other papers by Chi Pui Pang in
Google Scholar
PubMed
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
Hong Kong Eye Hospital, Hong Kong Special Administrative Region, China
Search for other papers by Kelvin Kam Lung Chong in
Google Scholar
PubMed
Purpose
This study aims to report correlations between thyroid-stimulating immunoglobulin (TSI) and both clinical and radiological parameters in recent-onset symptomatic thyroid eye disease (TED) patients.
Methods
A prospective cohort study of TED patients managed at the Chinese University of Hong Kong from January 2014 to May 2022. Serum TSI levels were determined with the functional assay. Outcomes included the Clinical Activity Score (CAS), marginal reflex distance1 (MRD1), extraocular muscle motility restriction (EOMy), exophthalmos, and diplopia. The radiological assessment included cross-sectional areas and signal of extraocular muscles on STIR-sequence MRI.
Results
A total of 255 (197 female) treatment-naive patients, with an average onset age of 50 ± 14 years (mean ± s.d.), were included. Elevated pre-treatment TSI level was observed in 223 (88%) patients. There was a weak positive correlation between TSI and CAS (r = 0.28, P = 0.000031), MRD1 (r = 0.17, P = 0.0080), and the size of the levator palpebrae superioris/superior rectus complex (r = 0.25, P = 0.018). No significant correlation existed between TSI and STIR signals. The AUC and optimal cut-off value for clinical active TED were 0.67 (95% CI: 0.60–0.75) and 284% (specificity: 50%, sensitivity: 85%). In total, 64 patients received intravenous methylprednisolone (IVMP) during the study interval, and they had a higher baseline TSI level than those who did not have IVMP (P = 0.000044). Serial post-IVMP TSI among the 62 patients showed a significant reduction compared to the baseline level (P < 0.001). Both the baseline and post-IVMP TSI levels, and percentages of TSI changes were comparable between patients who responded and did not respond to the first course of IVMP.
Conclusion
TSI can be a serum biomarker for the diagnosis, prognosis, and treatment response of TED. Further validation should be warranted.
Search for other papers by Véronique Raverot in
Google Scholar
PubMed
Search for other papers by Stéphanie Metrat in
Google Scholar
PubMed
Search for other papers by Pauline Perrin in
Google Scholar
PubMed
Search for other papers by Juliette Abeillon in
Google Scholar
PubMed
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
MacroTSH still interferes with TSH assays. We present here a case report illustrating the difficulties that can arise in such conditions and attempt to discuss the steps involved in diagnosis.
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Search for other papers by Stan R Ursem in
Google Scholar
PubMed
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Amsterdam Reproduction & Development, Amsterdam, The Netherlands
Search for other papers by Anita Boelen in
Google Scholar
PubMed
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Search for other papers by Jacquelien J Hillebrand in
Google Scholar
PubMed
Amsterdam Public Health, Amsterdam, The Netherlands
Search for other papers by Wendy P J den Elzen in
Google Scholar
PubMed
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Amsterdam Reproduction & Development, Amsterdam, The Netherlands
Department of Laboratory Medicine, Endocrine Laboratory, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan, Amsterdam, The Netherlands
Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
Objective
International guidelines concerning subclinical hyperthyroidism and thyroid cancer advice absolute cut-off values for aiding clinical decisions in the low range of thyroid-stimulating hormone (TSH) concentrations. As TSH assays are known to be poorly standardized in the normal to high range, we performed a TSH assay method comparison focusing on the low range.
Methods
Sixty samples, selected to cover a wide range of TSH concentrations (<0.01 to 120 mIU/L) with oversampling in the lower range (<0.4 mIU/L), were used for the method comparison between three TSH immunoassays (Cobas, Alinity and Atellica). In addition, 20 samples were used to assess the coefficient of variation from duplicate measurements in these three methods.
Results
The TSH immunoassays showed standardization differences with a bias of 7–16% for the total range and 1–14% for the low range. This could lead to a different classification of 1.5% of all measured TSH concentrations <0.40 mIU/L measured in our laboratory over the last 6 months, regarding the clinically important cut-off value of TSH = 0.1 mIU/L. As the imprecision of the immunoassays varied from 1.6–5.5%, this could lead to a similar reclassification as the bias between immunoassays.
Conclusions
We established the standardization differences of frequently used TSH assays for the total and low concentration ranges. Based on the proportional bias and the imprecision, this effect seems to have limited clinical consequences for the low TSH concentration range. Nevertheless, as guidelines mention absolute TSH values to guide clinical decision-making, caution must be applied when interpreting values close to these cut-offs.
Department of Clinical Sciences and Community Health, University of Milan, Italy
Search for other papers by Ilaria Muller in
Google Scholar
PubMed
Search for other papers by Anita Daturi in
Google Scholar
PubMed
Search for other papers by Matteo Varallo in
Google Scholar
PubMed
Search for other papers by Tiziana E Re in
Google Scholar
PubMed
Search for other papers by Davide Dazzi in
Google Scholar
PubMed
Search for other papers by Sara Maioli in
Google Scholar
PubMed
Search for other papers by Erica Crivicich in
Google Scholar
PubMed
Search for other papers by Francesco Di Marco in
Google Scholar
PubMed
Search for other papers by Virgilio Longari in
Google Scholar
PubMed
Search for other papers by Beatrice Dazzi in
Google Scholar
PubMed
Search for other papers by Massimo Castellani in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, University of Milan, Italy
Search for other papers by Giovanna Mantovani in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, University of Milan, Italy
Search for other papers by Maura Arosio in
Google Scholar
PubMed
Search for other papers by Mario Salvi in
Google Scholar
PubMed
Objective
We have previously observed thyroid dysfunction, i.e. atypical thyroiditis (painless thyrotoxicosis associated with non-thyroidal illness syndrome), in patients with severe acute respiratory syndrome coronavirus 2 disease (Covid-19). This study aimed to analyse the evolution of thyroid dysfunction over time.
Methods
One hundred eighty-three consecutive patients hospitalised for severe Covid-19 without known thyroid history were studied at hospital admission (baseline). Survivors were offered 12-month longitudinal follow-up including assessment of thyroid function, autoantibodies and ultrasound scan (US). Patients showing US focal hypoechoic areas suggestive of thyroiditis (focal hypoechogenicity) also underwent thyroid 99mTc or 123I uptake scan.
Results
At baseline, after excluding from TSH analysis, 63 out of 183 (34%) Covid-19 patients commenced on steroids before hospitalisation, and 12 (10%) showed atypical thyroiditis. Follow-up of 75 patients showed normalisation of thyroid function and inflammatory markers and no increased prevalence of detectable thyroid autoantibodies. Baseline US (available in 65 patients) showed focal hypoechogenicity in 28% of patients, of whom 82% had reduced thyroid 99mTc/123I uptake. The presence of focal hypoechogenicity was associated with baseline low TSH (P = 0.034), high free-thyroxine (FT4) (P = 0.018) and high interleukin-6 (IL6) (P = 0.016). Focal hypoechogenicity persisted after 6 and 12 months in 87% and 50% patients, respectively, but reduced in size. After 9 months, thyroid 99mTc/123I uptake partially recovered from baseline (+28%) but was still reduced in 67% patients.
Conclusions
Severe Covid-19 induces mild transient thyroid dysfunction correlating with disease severity. Focal hypoechogenicity, associated with baseline high FT4, IL6 and low TSH, does not seem to be related to thyroid autoimmunity and may persist after 1 year although decreasing in size. Long-term consequences seem unlikely.
Search for other papers by Federica D’Aurizio in
Google Scholar
PubMed
Search for other papers by Alessia Biasotto in
Google Scholar
PubMed
Search for other papers by Claudia Cipri in
Google Scholar
PubMed
Search for other papers by Franco Grimaldi in
Google Scholar
PubMed
Search for other papers by Jessica Zucco in
Google Scholar
PubMed
Search for other papers by Stefania Marzinotto in
Google Scholar
PubMed
Department of Medicine, University of Udine, Udine, Italy
Search for other papers by Francesco Curcio in
Google Scholar
PubMed
Search for other papers by Salvatore Benvenga in
Google Scholar
PubMed
Introduction
Thyroid function tests (TFT) are extensively used in daily clinical practice. Here, we described a case of incongruent TFT both in a pregnant woman and in her newborn.
Case presentation
A 32-year-old woman, diagnosed with autoimmune thyroiditis during her first pregnancy, was monitored during her second gestation. At week 5 + 2 days, thyroid-stimulating hormone (TSH) and free thyroxine (FT4) values (Dimension VISTA 1500, Siemens Healthineers) were within normal limits. At week 19 + 5 days, TSH remained normal while FT4 increased approximately by three-fold. FT4 inconsistency was with both TSH and the clinical status since she continued to be clinically euthyroid. On the same serum sample, thyroid autoantibodies were negative. At week 25 + 4 days, the patient complained of palpitations and dyspnea, with tachycardia. Even though TSH was normal, high levels of both FT4 and free triiodothyronine (FT3) were interpreted as evidence of thyroid overactivity and methimazole was started. TFT of the pregnant woman continued to be monitored throughout gestation. Postpartum FT4 and FT3 gradually returned to normal. TFT, performed on the daughter’s serum, 3 days after birth, showed the same inconsistency as her mother but without clinical signs of congenital hyperthyroidism. Based on the clinical and laboratory setting, the presence of circulating autoantibodies against T3 and T4 (THAb) was suspected and demonstrated by radioimmunoprecipitation.
Conclusion
Analytical interferences should be supposed when TFT do not fit with the clinical picture and despite their infrequency, THAb must also be considered. To our knowledge, this is the first case describing the passage of THAb to the newborn.
Search for other papers by Eijun Nishihara in
Google Scholar
PubMed
Search for other papers by Yoshitaka Hobo in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
Search for other papers by Yasuhiro Ito in
Google Scholar
PubMed
Search for other papers by Miyoko Higuchi in
Google Scholar
PubMed
Search for other papers by Mitsuyoshi Hirokawa in
Google Scholar
PubMed
Search for other papers by Mitsuru Ito in
Google Scholar
PubMed
Search for other papers by Shuji Fukata in
Google Scholar
PubMed
Search for other papers by Mitsushige Nishikawa in
Google Scholar
PubMed
Search for other papers by Takashi Akamizu in
Google Scholar
PubMed
Objective
This study aimed to elucidate disproportionately low serum thyroglobulin (Tg) values in Tg antibody (TgAb)-positive patients with structural recurrence of papillary thyroid carcinoma (PTC) using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Design
A retrospective study was performed on 176 patients in whom Tg and TgAb levels were measured between 2016 and 2021. Several comprehensive analyses of Tg-LC-MS/MS with an electrochemiluminescence immunoassay for Tg (Tg-ECLIA) were conducted using serum samples.
Methods
TgAb-positive patients who underwent total thyroidectomy with multiple lung metastases due to PTC were evaluated using Tg-LC-MS/MS and Tg-ECLIA. Tg expression in lymph node metastases and metastatic lesions was evaluated by immunohistochemistry and Tg levels of aspiration washouts were also evaluated. Two in vitro assays were performed to elucidate TgAb interference.
Results
Tg concentrations of negative TgAb in both assays were similar (R2= 0.99; n = 52). Patients with structural recurrence showed higher Tg values with Tg-LC-MS/MS than with Tg-ECLIA. The undetectable proportion was significantly lower with Tg-LC-MS/MS (31.6%, 6/19) than with Tg-ECLIA (68.4%, 13/19; P = 0.023). The spike-recovery rate and Tg concentrations determined by the serum mixture text (n = 29) were significantly reduced to 75.0% (118.3–88.7%) and 81.3% (107.0–87.0%), respectively, with TgAb using Tg-ECLIA (both P < 0.001) confirming assay interference but not using Tg-LC-MS/MS (91.8–92.3%, P = 0.77 and 98.4–100.8%, P = 0.18, respectively).
Conclusions
TgAb had no effect on the Tg-LC-MS/MS assay but yielded 19–25% lower values in Tg-ECLIA. Tg-LC-MS/MS is preferable for monitoring serum Tg levels in TgAb-positive patients, although those with structural recurrence often had disproportionally low Tg values.
